Giulio Francolini, Radiation Oncologist at Careggi University Hospital, shared a post on X:
“10 years results from the FLAME trial: addition of an isotoxic focal boost to the standard treatment for intermediate- and high-risk prostate cancer patients increases the 10-year bDFS and DFS significantly.”
More posts featuring Giulio Francolini.
